Clinical symptoms of mitral valve prolapse are related to hypomagnesemia and attenuated by magnesium supplementation
Lichodziejewska B, Kłoś J, Rezler J, Grudzka K, Dłuzniewska M, Budaj A, Ceremuzyński L
The American journal of cardiology · 22 citas
Etiquetas de revisión
Financiación no declaradaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación no declarada
Publicación
- Publicado
- 1997-03-01 · Am J Cardiol · vol. 79 · número 6 · págs. 768–772
- Editorial
- Elsevier BV
- Citado
- 52 citas · más que el 91% de estudios similares · 3.2× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 25 trabajos
- Acceso
- De pago
- Áreas de investigación
- Magnesium in Health and Disease · Cardiac Valve Diseases and Treatments · Cardiac Health and Mental Health
- Palabras clave
- mitral valve prolapse, hypomagnesemia, magnesium supplementation, serum magnesium, symptom severity, catecholamine excretion, norepinephrine, epinephrine, anxiety, quality of life
- MeSH
- humans, mitral valve prolapse, magnesium deficiency, magnesium, catecholamines, echocardiography, statistics, nonparametric, cross-over studies, double-blind method, anxiety, adolescent, adult, middle aged, female, male
7 autores
- Barbara Lichodziejewska🇵🇱 · autor de correspondenciaGrochowski Hospital
- Jadwiga Kłoś🇵🇱Grochowski Hospital
- Joanna Rezler🇵🇱Grochowski Hospital
- Katarzyna Grudzka🇵🇱Grochowski Hospital
- M Dłuzniewska🇵🇱Grochowski Hospital
- Andrzej Budaj🇵🇱Grochowski Hospital
- Leszek Ceremuzyński🇵🇱Grochowski Hospital
Resumen
El texto original del estudio, en el idioma en que se publicó.
Mitral valve prolapse syndrome (MVP) is a frequent disorder characterized by a number of complaints which lessen the quality of life. The pathogenesis of MVP symptoms has not been fully elucidated. Hyperadrenergic activity and magnesium deficiency have been suggested. This study was designed to verify the concept that heavily symptomatic MVP is accompanied by hypomagnesemia and to elucidate whether magnesium supplementation alleviates the symptoms and influences adrenergic activity. We assessed serum magnesium in 141 subjects with heavily symptomatic primary MVP and in 40 healthy controls. Decreased serum magnesium was found in 60% of patients and in 5% of controls (p <0.0001). Patients with low serum magnesium were subjected to magnesium or placebo supplementation in a double-blind, crossover fashion. Typical symptoms of MVP (n = 13), intensity of anxiety, and daily excretion of catecholamines were determined. After 5 weeks, the mean number of symptoms per patient decreased from 10.4 +/- 2.1 to 5.6 +/- 2.5 (p <0.0001), and a significant reduction in weakness, chest pain, dyspnea, palpitations, and anxiety was observed. Increased noradrenaline excretion before and after magnesium was seen in 63% and 17% of patients, respectively (p <0.01). Mean daily excretion of noradrenaline and adrenaline was significantly diminished after magnesium. It is concluded that many patients with heavily symptomatic MVP have low serum magnesium, and supplementation of this ion leads to improvement in most symptoms along with a decrease in catecholamine excretion.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.